Tag: Migraine alternatives

According to the Migraine Research Foundation, migraine affects over 39 million Americans, many of whom rely on acute treatments like Ubrelvy (ubrogepant) to stop an attack. However, if Ubrelvy is ineffective, poorly tolerated, or not covered by insurance, it's natural to seek an alternative medication for Ubrelvy. Fortunately, significant advances in migraine pharmacology offer a wide and expanding range of options.

While the United States Adopted Name (USAN) for the antimigraine agent pizotifen is pizotyline, the drug is not approved for use by the U.S. Food and Drug Administration (FDA). This means that despite having a designated American name, the medication is not commercially available to patients in the United States.